Document is current
Any future updates will be listed below
-
Authors
Li, Ping
Li, Chaofan
Liang, Shuang
Sun, Xuefeng
Guo, Xinru
Xu, Xieguanxuan
Hao, Lichen
Chen, Xiangmei
Feng, Zhe
Cai, Guangyan
-
Funding
Funding for this research was provided by:
Sanofi Genzyme
- License Information
-
More Information
Article History
Received: 23 January 2026
Accepted: 11 March 2026
First Online: 15 April 2026
Change Date: 10 May 2026
Change Type: Update
Change Details: The original article has been updated due to retrospective open access.
Declarations
:
: Lichen Hao is an employee of Sanofi, and reports owning stock in Sanofi. Ping Li, Zhe Feng, Xuefeng Sun, Shuang Liang, Chaofan Li, Xinru Guo, Xieguanxuan Xu, Xiangmei Chen and Guangyan Cai declare that they have no competing interests.
: This study was performed in accordance with the ethical principles of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice, Good Pharmacoepidemiology Practice, and the applicable local legislation. The protocol for this study was reviewed by the First Medical Center of Chinese PLA General Hospital Institutional Review Board (IRB); however, as all data used in this study were de-identified, the IRB deemed this study exempt from requiring approval or further review. Furthermore, the requirement for patients’ informed consent was waived by the IRB because all personal identifiers were removed to ensure patient confidentiality. Permission was obtained from the database provider (Optum) to access and use the de-identified administrative claims data for this study.
